Otonomy Appoints Anthony J. Yost Chief Commercial Officer
October 21, 2014Otonomy appoints Anthony J. Yost as chief commercial officer, who brings 30 years of experience in pharmaceutical product sales and marketing that includes building and managing commercial teams at multiple companies.
More »
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
October 21, 2014Esperion therapeutics closes its follow-on public offering of 4,887,500 shares of common stock at a price of $20.00 per share, bringing the net proceeds in the offering to $91.6 million.
More »
Xagenic Appoints Timothy I. Still as President & Chief Executive Officer
October 16, 2014Xagenic appoints Timothy I. Still as president and CEO, as well as serve as a member of its board of directors. In conjunction with Still's appointment, Bruce Cohen stepped down from his position on the company's board.
More »